Welcome to our dedicated page for Pure Bioscience SEC filings (Ticker: PURE), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Tracking the science behind Pure Bioscience’s silver dihydrogen citrate platform is tough—its 10-K alone weaves antimicrobial toxicology, EPA approvals, and patent minutiae into hundreds of pages. If you have ever wondered where to locate Pure Bioscience insider trading Form 4 transactions or the latest R&D spending footnotes, you are not alone.
Stock Titan turns that complexity into clarity. Our AI reads every Pure Bioscience quarterly earnings report 10-Q filing the moment it hits EDGAR, delivering plain-English highlights of revenue from SDC disinfectants, cash-burn trends, and regulatory milestones. Need governance intel? We surface Pure Bioscience proxy statement executive compensation figures alongside peer benchmarks and flag Pure Bioscience executive stock transactions Form 4 in real time. Investors searching for Pure Bioscience SEC filings explained simply can drill into:
- 10-K—our "Pure Bioscience annual report 10-K simplified" summary points out antimicrobial market size assumptions and patent expiry timelines.
- 8-K—see Pure Bioscience 8-K material events explained whenever new distribution agreements or FDA feedback are announced.
- Form 4—instant alerts on Pure Bioscience Form 4 insider transactions real-time so you can gauge management conviction.
Whether you are modeling cash runway or benchmarking sustainability claims, our platform equips you with Pure Bioscience earnings report filing analysis in minutes, not hours. Start understanding Pure Bioscience SEC documents with AI today and turn dense biotech disclosures into actionable insight.
PURE Bioscience, Inc. announced a leadership change in its executive team. Jeffrey Kitchell has been appointed as the company’s President, effective November 17, 2025, while continuing in his existing role as Corporate Secretary. Robert Bartlett remains Chief Executive Officer, principal executive officer, and a member of the board, but no longer holds the President title.
Kitchell, age 55, has been Vice President of Operations since April 2023 and has served as Corporate Secretary since 2019. He has been with the company since 2001 in a variety of roles overseeing day-to-day operations, legal affairs, and intellectual property, and holds a Bachelor’s degree in Business Administration from the University of Phoenix. His compensation terms are expected to follow the company’s standard officer indemnification and benefit programs, with no new special arrangements or related-party relationships disclosed.
PURE Bioscience, Inc. filed its annual report for the year ended July 31, 2025. The company reported net product sales of $2.20 million, up from $1.96 million in 2024, and a net loss of $2.4 million versus a $3.4 million loss last year. Cash was $334,000 as of July 31, 2025, and auditors expressed substantial doubt about the company’s ability to continue as a going concern.
The business focuses on proprietary silver dihydrogen citrate (SDC) antimicrobial products, including PURE Hard Surface (EPA-registered) and PURE Control (FDA Food Contact Notifications for poultry and produce). Customer concentration remains notable; the largest customer represented 18% of net product sales in 2025. As of October 29, 2025, there were 111,886,473 shares outstanding. The company completed a private placement of convertible debt with $2.0 million in net proceeds during fiscal 2025 and indicates the need for additional capital to fund operations.
PURE continues to pursue food-safety markets through distributors and partnerships while navigating extensive regulatory requirements from the EPA, FDA, USDA and foreign authorities.
PURE Bioscience (PURE)
FAQ
What is the current stock price of Pure Bioscience (PURE)?
What is the market cap of Pure Bioscience (PURE)?
